These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 34021797)

  • 21. Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir.
    El-Awady M; Elmansi H; Belal F; Shabana RA
    J Fluoresc; 2022 Sep; 32(5):1941-1948. PubMed ID: 35771341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of favipiravir in the treatment of COVID-19.
    Joshi S; Parkar J; Ansari A; Vora A; Talwar D; Tiwaskar M; Patil S; Barkate H
    Int J Infect Dis; 2021 Jan; 102():501-508. PubMed ID: 33130203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.
    Kundu S; Sarkar D
    Mini Rev Med Chem; 2022; 22(2):232-247. PubMed ID: 34254915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
    Khamis F; Al Naabi H; Al Lawati A; Ambusaidi Z; Al Sharji M; Al Barwani U; Pandak N; Al Balushi Z; Al Bahrani M; Al Salmi I; Al-Zakwani I
    Int J Infect Dis; 2021 Jan; 102():538-543. PubMed ID: 33181328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful.
    Hirouchi T; Ota S; Mashima D; Boku R; Yoshida Y; Iwata K; Shinada K; Matsumoto T; Morikawa M; Sato T; Shinoda M; Kamachi K; Shinkai M
    J Infect Chemother; 2021 Feb; 27(2):379-383. PubMed ID: 33268271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19.
    Lutz JD; Mathias A; German P; Pikora C; Reddy S; Kirby BJ
    Clin Pharmacol Ther; 2021 Apr; 109(4):1116-1124. PubMed ID: 33501997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical safety of remdesivir therapy in COVID-19 patients with renal insufficiency.
    Park S; Kim AR; Lee J; Kang SW; Sung H; Kim MN; Chang E; Bae S; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Song EH; Chong YP
    J Infect Chemother; 2024 Apr; 30(4):366-370. PubMed ID: 37935348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights.
    Parlak C; Alver Ö; Ouma CNM; Rhyman L; Ramasami P
    Drug Res (Stuttg); 2022 Jan; 72(1):34-40. PubMed ID: 34535038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extracorporeal Membrane Oxygenation for COVID-19-Associated Multisystem Inflammatory Syndrome in a 5-year-old.
    Schwartz SP; Walker TC; Kihlstrom M; Isani M; Smith MM; Smith RL; McLean SE; Clement KC; Phillips MR
    Am Surg; 2022 Feb; 88(2):174-176. PubMed ID: 33372818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.
    Marra F; Smolders EJ; El-Sherif O; Boyle A; Davidson K; Sommerville AJ; Marzolini C; Siccardi M; Burger D; Gibbons S; Khoo S; Back D
    Drugs R D; 2021 Mar; 21(1):9-27. PubMed ID: 33336316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
    Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
    J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
    Singh A; Kamath A
    Expert Opin Drug Saf; 2021 Dec; 20(12):1559-1564. PubMed ID: 34328807
    [No Abstract]   [Full Text] [Related]  

  • 34. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
    Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
    J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
    Choi SW; Shin JS; Park SJ; Jung E; Park YG; Lee J; Kim SJ; Park HJ; Lee JH; Park SM; Moon SH; Ban K; Go YY
    Antiviral Res; 2020 Dec; 184():104955. PubMed ID: 33091434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorescence of ocular surface in a Covid -19 patient after Favipiravir treatment: a case report.
    Doran MA; Aytogan H; Ayıntap E
    Virol J; 2021 Jul; 18(1):146. PubMed ID: 34256791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.
    Ackley TW; McManus D; Topal JE; Cicali B; Shah S
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
    Manosuthi W; Jeungsmarn S; Okada P; Suwanvattana P; Wongboot W; Thawornwan U; Charoenpong L; Wiboonchutikul S; Uttayamakul S; Pongpirul WA; Wachirapan A; Warachit P
    Jpn J Infect Dis; 2021 Sep; 74(5):416-420. PubMed ID: 33518623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Favipiravir-induced fever in coronavirus disease 2019: A report of two cases.
    Takoi H; Togashi Y; Fujimori D; Kaizuka H; Otsuki S; Wada T; Takeuchi Y; Abe S
    Int J Infect Dis; 2020 Dec; 101():188-190. PubMed ID: 32992014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis.
    Sörgel F; Malin JJ; Hagmann H; Kinzig M; Bilal M; Eichenauer DA; Scherf-Clavel O; Simonis A; El Tabei L; Fuhr U; Rybniker J
    J Antimicrob Chemother; 2021 Feb; 76(3):825-827. PubMed ID: 33251541
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.